+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Global Metabolic Partnering 2014-2021: Deal Trends, Players and Financials

  • ID: 2229064
  • Report
  • March 2021
  • Region: Global
  • 700 Pages
  • CurrentPartnering


  • 23andMe
  • Aelan Cell Technologies
  • Allergan
  • Antisense Therapeutics
  • Autotelic
  • Bina Technologies
Global Metabolic Partnering 2014 to 2021 provides the full collection of Metabolic disease deals signed between the world’s pharmaceutical and biotechnology companies since 2014.
  • Trends in Metabolic partnering deals
  • Financial deal terms for headline, upfront and royalty by stage of development
  • Metabolic partnering agreement structure
  • Metabolic partnering contract documents
  • Top Metabolic deals by value
  • Most active Metabolic dealmakers
Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor’s product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Metabolic disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Metabolic deals.

The report presents financial deal terms values for Metabolic deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

The initial chapters of this report provide an orientation of Metabolic dealmaking trends.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in Metabolic dealmaking since 2014 covering trends by year, deal type, stage of development, technology type and therapeutic indication.

Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.

Chapter 4 provides a review of the leading Metabolic deals since 2014. Deals are listed by headline value. The chapter includes the top 25 most active Metabolic dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 5 provides comprehensive access to Metabolic deals since 2014 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of all Metabolic partnering deals by specific Metabolic target announced since 2014. The chapter is organized by specific Metabolic therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all Metabolic partnering deals signed and announced since 2014. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Metabolic partnering and dealmaking since 2014.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Metabolic technologies and products.

Report Scope

Global Metabolic Partnering 2014 to 2021 is intended to provide the reader with an in-depth understanding and access to Metabolic trends and structure of deals entered into by leading companies worldwide.

Global Metabolic Partnering 2014 to 2021 includes:
  • Trends in Metabolic dealmaking in the biopharma industry since 2014
  • Analysis of Metabolic deal structure
  • Access to headline, upfront, milestone and royalty data
  • Access to hundreds of Metabolic deal contract documents
  • Comprehensive access to over 1100 Metabolic deal records
  • The leading Metabolic deals by value since 2014
  • Most active Metabolic dealmakers since 2014
The report includes deals for the following indications: Acromegaly, Addison's disease, Cirrhosis, Cushing's syndrome, Diabetes, Type 1, Type 2, Insipidus, Fatty liver, Gallstones, Goitre, Growth hormone disorders, Gynaecomastia, Inborn errors of metabolism, Phenylketonuria, Hyperaldosteronism, Hypercalcaemia, Hyperthyroidism, Hypocalcaemia, Hypogonadism, Hypopituitarism, Hypothyroidism, Liver disease, Nonalcoholic steatohepatitis (NASH), Lysosomal storage disorders, Nutrition and vitamins, Rickets, Pheochromocytoma, Primary bilary cirrhosis, Prolactinemia, Short stature, Syndrome of Inappropriate Antidiuretic Hormone (SIADH), Thyroid disease, plus other metabolic indications.

In Global Metabolic Partnering 2014 to 2021, available deals and contracts are listed by:
  • Headline value
  • Upfront payment value
  • Royalty rate value
  • Stage of development at signing
  • Deal component type
  • Technology type
  • Specific therapy indication
Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Metabolic Partnering 2014-2021 report provides comprehensive access to available deals and contract documents for over 1100 metabolic deals.

Analyzing actual contract agreements allows assessment of the following:
  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How are the sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?
Note: Product cover images may vary from those shown


  • 23andMe
  • Aelan Cell Technologies
  • Allergan
  • Antisense Therapeutics
  • Autotelic
  • Bina Technologies
Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Metabolic dealmaking
2.1. Introduction
2.2. Metabolic partnering over the years
2.3. Metabolic partnering by deal type
2.4. Metabolic partnering by industry sector
2.5. Metabolic partnering by stage of development
2.6. Metabolic partnering by technology type
2.7. Metabolic partnering by therapeutic indication

Chapter 3 - Financial deal terms for Metabolic partnering
3.1. Introduction
3.2. Disclosed financials terms for Metabolic partnering
3.3. Metabolic partnering headline values
3.4. Metabolic deal upfront payments
3.5. Metabolic deal milestone payments
3.6. Metabolic royalty rates

Chapter 4 - Leading Metabolic deals and dealmakers
4.1. Introduction
4.2. Most active in Metabolic partnering
4.3. List of most active dealmakers in Metabolic
4.4. Top Metabolic deals by value

Chapter 5 - Metabolic contract document directory
5.1. Introduction
5.2. Metabolic partnering deals where contract document available

Chapter 6 - Metabolic dealmaking by therapeutic target
6.1. Introduction
6.2. Deals by Metabolic therapeutic target

Appendix 1 - Directory of Metabolic deals by company A-Z since 2014
Appendix 2 - Directory of Metabolic deals by deal type since 2014
Appendix 3 - Directory of Metabolic deals by stage of development since 2014
Appendix 4 - Directory of Metabolic deals by technology type since 2014
Further reading on dealmaking
Deal type definitions

Table of figures
Figure 1: Metabolic partnering since 2014
Figure 2: Metabolic partnering by deal type since 2014
Figure 3: Metabolic partnering by industry sector since 2014
Figure 4: Metabolic partnering by stage of development since 2014
Figure 5: Metabolic partnering by technology type since 2014
Figure 6: Metabolic partnering by indication since 2014
Figure 7: Metabolic deals with a headline value
Figure 8: Metabolic deals with upfront payment values
Figure 9: Metabolic deals with milestone payment
Figure 10: Metabolic deals with royalty rates
Figure 11: Active Metabolic dealmaking activity sinc 2014
Figure 12: Top Metabolic deals by value since 2014
Note: Product cover images may vary from those shown
  • 2XU
  • 3SBio
  • 5LINX
  • 23andMe
  • A*STAR Agency for Science
  • Technology and Research
  • AB-Biotics
  • Abbott Laboratories
  • Abbvie
  • Abby Grace Foundation
  • Abeona Therapeutics
  • Abiogen Pharma
  • Academic Drug Discovery Consortium
  • Academy Medical
  • Acasti Pharma
  • Accord Healthcare
  • Acerus
  • Aceto Corporation
  • Acon Labs
  • Actavis (name changed to Allergan)
  • Activhealth
  • Acurian
  • Admera Health
  • Adocia
  • Advance Pharmaceutical
  • Adverum Biotechnologies
  • Aelan Cell Technologies
  • Aero Pump
  • AEterna Zentaris
  • Aetna
  • Aevi Genomic Medicine
  • Afimmune
  • AgaMatrix
  • AgBiome
  • Agilent Technologies
  • Aguettant
  • Ajinomoto
  • Akero Therapeutics
  • Akers Biosciences
  • AKSA Medical
  • Akston Biosciences
  • Albany Molecular Research
  • Albert Einstein College of Medicine
  • Albion
  • Albumedix
  • Alcon Laboratories
  • Alcresta
  • Alexion Pharmaceuticals
  • ALK-Abello
  • Allegro Ophthalmics
  • Allele Biotechnology and Pharmaceuticals
  • Allergan
  • AllerGenis
  • Alliance Pharma
  • All Star Health Brands
  • Alnylam Pharmaceuticals
  • ALR Technologies
  • Alteogen
  • Alzheimer's Association
  • Amarna Therapeutics
  • Amazentis
  • Ambrosia Nutraceuticals
  • Ambys Medicines
  • A Menarini Diagnostics
  • American Diabetes Association
  • American Gene Technologies
  • American Society for Parenteral and Enteral Nutrition
  • Amgen
  • Amicus Therapeutics
  • Amneal Pharmaceuticals
  • AMRA
  • Amunix
  • Amyris
  • Andromeda Biotech
  • AnGes MG
  • ANI Pharmaceuticals
  • Anji Pharma
  • Anokion
  • Antares Pharma
  • Antaros Medical
  • Antisense Therapeutics
  • AOP Orphan Pharmaceuticals
  • Apollo Endosurgery
  • Apollo Sugar
  • Apricus Biosciences
  • Arcadia Resources
  • ARCH Personalized Medicine Initiative
  • Arcturus Therapeutics
  • Arecor
  • argenx
  • Argon Medical Devices
  • Arix Bioscience
  • Arjuna Naturals
  • Arkray USA
  • Artizan Biosciences
  • Arzeda
  • Ascensia Diabetes Care
  • Ascletis
  • Aspect Biosystems
  • Aspen Holding
  • Astellas Pharma
  • AstraZeneca
  • AstraZeneca HealthCare Foundation
  • Attain Health
  • Atvio Biotech
  • Audentes Therapeutics
  • Australian Department of Health and Ageing
  • Australian Foundation for Diabetes Research
  • AutoGenomics
  • Autotelic
  • Avion Pharmaceuticals
  • Avivagen
  • Avrobio
  • Awamedica
  • AXIM Biotechnologies
  • Axxess Pharma
  • Aytu BioScience
  • Bambino Gesu Children’s Hospital
  • Banting & Best Diabetes Centre (BBDC)
  • BASF
  • Baxter International
  • Bayer
  • Baylor College of Medicine
  • Beacon Discovery
  • Becton Dickinson
  • Beijing Sun-Novo Pharmaceutical Research
  • Benchworks
  • Bened Biomedical
  • Bertin Pharma
  • Best Choice
  • Beta-O2
  • Better Living Now
  • Beyond Type 1
  • BGN Technologies
  • BHV Pharmaceuticals
  • Bicycle Therapeutics
  • Bigfoot Biomedical
  • Bina Technologies
  • Bio-Rad Laboratories
  • BioCision
  • Biocodex Microbiota Foundation
  • Biodel
  • Biodelta Nutraceuticals
  • BioGaia
  • Biogen
  • Biohit
  • Bioinn Molecular Diagnosis
  • BiolineRX
  • Biomedical Catalyst Fund (UK)
  • BioMed X Innovation Center
  • BiopharmX
  • BioRestorative Therapies
  • Biosequel
  • BioTelemetry
  • BioViva Sciences
  • Bird Foundation
  • Blue Diamond Growers
  • Blue Mesa Health
  • BlueOcean Nutrascience
  • Boehringer Ingelheim
  • Bora Pharmaceuticals
  • Boston Scientific
  • Boston Therapeutics
  • Brigham and Women's Hospital
  • Bristol-Myers Squibb
  • Bruker
  • c-LEcta
Note: Product cover images may vary from those shown
  • The publisher reports provide insight into the trends and terms of partnering deals in the global life sciences sector.
  • The publisher reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.
  • The publisher analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.
  • The publisher reports source deal data from our proprietary deals and alliances database. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal.
  • The data in the deals and alliances database is obtained from secondary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.

The publisher provides comprehensive coverage of the following partnering or deal types:

  • Asset purchase
  • Assignment
  • Co-development
  • Co-market
  • Co-promotion
  • Collaborative R&D
  • Contract service
  • Cross-licensing
  • Development
  • Distribution
  • Equity purchase
  • Evaluation
  • Grant
  • Joint venture
  • Licensing
  • Loan
  • Manufacturing
  • Marketing
  • Option
  • Promotion
  • Research
  • Royalty financing
  • Settlement
  • Spin out
  • Sub license
  • Supply
  • Termination
  • Warrant

Every deal record is fully categorized and includes the following data, where available:

  • Industry sector
  • Therapy areas
  • Technology type
  • Deal components
  • Financial terms
  • Stage of development
  • Exclusivity
  • Asset type
  • Geographic focus
  • Excluded geography
  • Company press release
  • SEC filing data including contract document

All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.